Conduit Pharmaceuticals Faces Nasdaq Listing Rule Non-Compliance
Ticker: CDTTW · Form: 8-K · Filed: Aug 16, 2024 · CIK: 1896212
| Field | Detail |
|---|---|
| Company | Conduit Pharmaceuticals Inc. (CDTTW) |
| Form Type | 8-K |
| Filed Date | Aug 16, 2024 |
| Risk Level | high |
| Pages | 4 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001, $11.50, $15 million, $50 million |
| Sentiment | bearish |
Sentiment: bearish
Topics: listing-rule-violation, delisting-risk, sec-filing
TL;DR
Nasdaq says Conduit Pharma ain't playing by the rules, might get kicked off.
AI Summary
Conduit Pharmaceuticals Inc. announced on August 15, 2024, that it received a notice from the Nasdaq Stock Market indicating non-compliance with listing rules. The company is currently evaluating its options to regain compliance and has not yet determined the full impact on its listing status.
Why It Matters
This filing signals potential delisting from Nasdaq, which could significantly impact the company's liquidity, stock price, and ability to raise capital.
Risk Assessment
Risk Level: high — Receiving a notice of non-compliance with Nasdaq listing rules poses a significant risk of delisting, which can severely impact stock liquidity and valuation.
Key Players & Entities
- Conduit Pharmaceuticals Inc. (company) — Registrant
- Nasdaq Stock Market (company) — Exchange where listing rules are being violated
- August 15, 2024 (date) — Date of the notice
FAQ
What specific Nasdaq listing rule(s) did Conduit Pharmaceuticals Inc. fail to meet?
The filing states that Conduit Pharmaceuticals Inc. received a notice from the Nasdaq Stock Market indicating non-compliance with certain listing rules, but does not specify which rules were violated.
What is the potential consequence of this non-compliance for Conduit Pharmaceuticals Inc.?
The potential consequence is the delisting of the company's securities from the Nasdaq Stock Market.
What actions is Conduit Pharmaceuticals Inc. taking in response to the notice?
The company is currently evaluating its options to regain compliance with Nasdaq's listing requirements.
Has Conduit Pharmaceuticals Inc. previously been subject to similar notices?
The provided text does not contain information about previous notices of non-compliance.
When did Conduit Pharmaceuticals Inc. receive this notice of non-compliance?
Conduit Pharmaceuticals Inc. received the notice on August 15, 2024.
Filing Stats: 1,082 words · 4 min read · ~4 pages · Grade level 13.8 · Accepted 2024-08-16 16:59:25
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share CDT The Nasdaq
- $11.50 — of Common Stock at an exercise price of $11.50 CDTTW The Nasdaq Stock Market LLC
- $15 million — lue of publicly held shares of at least $15 million (the "MVPHS Requirement"). In accorda
- $50 million — value of listed securities of at least $50 million (the "MVLS Requirement"). In accordan
Filing Documents
- form8-k.htm (8-K) — 46KB
- 0001493152-24-032854.txt ( ) — 264KB
- cdt-20240815.xsd (EX-101.SCH) — 4KB
- cdt-20240815_def.xml (EX-101.DEF) — 26KB
- cdt-20240815_lab.xml (EX-101.LAB) — 36KB
- cdt-20240815_pre.xml (EX-101.PRE) — 25KB
- form8-k_htm.xml (XML) — 6KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: August 16, 2024 CONDUIT PHARMACEUTICALS INC. By: /s/ Dr. David Tapolczay Name: Dr. David Tapolczay Title: Chief Executive Officer